Tuesday, December 23, 2014
N30 Pharmaceuticals Names New CEO
Boulder-based N30 Pharmaceuticals has named Jon Congleton as the company's new President and CEO, the company said Monday. Congleton also joins the company's board. Congleton previously served at Teva Pharmaceuticals. N30 is developing small molecule drugs aimed at treating cystic fibrosis. N30 is venture backed by Wellington Management, RA Capital Management, Jennison Associates, Rock Springs Capital Management, Sabby Management, and Deerfield Management.